TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05559008
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Study: NCT04789304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06388772
Drug: QHRD106 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
Study: NCT06388772
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05079451
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Study: NCT05182944
Drug: A：non-pCR patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study: NCT05182944
Drug: B：non-pCR patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study: NCT05182944
Drug: A：pCR patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study: NCT05182944
Drug: B：pCR patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study: NCT04821687
Drug: Madopar Tab. 125 or Perkin Tab. 25-100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
Study: NCT00215917
Drug: D-serine 2100 mg daily
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05573230
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05232552
Drug: induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
Study: NCT03787082
Drug: Placebo Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile water (15mL) mouth rinse for 1 minute
Study: NCT04940026
Drug: [14C]-SAR439859 microtracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion Intravenous
Study: NCT04940026
Drug: [14C]-SAR439859
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution Oral
Study: NCT05663892
Drug: Biktarvy 50/200/25 Tab
Normalized name: BIKTARVY 50/200/25 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
Study: NCT05663892
Drug: Estradiol Tablets
Normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking \> 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher.
Study: NCT05697952
Drug: E1K 1,200 ㎍/joint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of E1K 1,200 ㎍/joint/ml on target lesion
Study: NCT05697952
Drug: E1K 2,400 ㎍/joint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of E1K 2,400 ㎍/joint/ml on target lesion
Study: NCT05697952
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 3ml saline on target lesion
Study: NCT05799924
Drug: non steroidal anti inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal contraception can suppress ovulation, NSAIDS can ease pain
Study: NCT05449899
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
Study: NCT06297512
Drug: Radiotherapy, Temozolomide, Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);
Study: NCT04677179
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered SC
Study: NCT04677179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered SC
Study: NCT06392074
Drug: US License Enbrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06392074
Drug: EU Source Enbrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05090280
Drug: PF614 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF614 solution is an oxycodone prodrug
Study: NCT05004571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT03149211
Drug: current standard HAART treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive current standard HAART treatment as the active control group.
Study: NCT05188339
Drug: 4% sodium citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months.
Study: NCT05188339
Drug: heparin group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
Study: NCT04880109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo capsule once daily for 14 days
Study: NCT06610305
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg/day delivered via weekly patch
Study: NCT06609941
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist.
Study: NCT06609759
Drug: Standard chemotherapy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.
Study: NCT06189638
Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
Study: NCT05528887
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
Study: NCT04686643
Drug: AGSAVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine, Valsartan, Indapamide
Study: NCT06425978
Drug: Cellular Matrix / A-CP-HA Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina.
Study: NCT05039099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo by IV.
Study: NCT05079880
Drug: 300 mg of caffeine citrate infusion
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
Study: NCT05079880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
Study: NCT05017987
Drug: ATB-101, ATB-1011, ATB-1012
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Test drug~   - Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin
Study: NCT04991714
Drug: Lactisole
Approvals — FDA: no, EMA: no, PMDA: no
Description: sweet taste inhibitor (decreases sweetness)
Study: NCT04991714
Drug: Rebaudioside M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetener (increases sweetness)
Study: NCT06140420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT06071975
Drug: Adezunap (AP707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06071975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05469750
Drug: Dalpiciclib+ letrozole +capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continue medication to disease progression
Study: NCT06154109
Drug: Xiaopi granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
Study: NCT06154109
Drug: Xiaopi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
Study: NCT06154109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo does not contain any active pharmaceutical ingredients .
Study: NCT04292184
Drug: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
Study: NCT04950400
Drug: Carrelizumab + chemotherapy + apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
Study: NCT02556411
Drug: Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
Study: NCT05378048
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
Study: NCT06414473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered thrice daily (with food) using a sublingual route of administration
Study: NCT00320827
Drug: CS-1008 (humanized anti-DR5 antibody)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04814875
Drug: ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design.
Study: NCT05438706
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
Study: NCT00000731
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06088147
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A standard derma pen 12 pins with of 0,5 mm depth was used, dermapen as a tool of infusion of our treatments works in a few ways to target hair loss, firstly by breaking down the scar tissue that covers or compromises the hair follicles which are not growing, stimulating new hair growth and also by enhancing infusion of mesotherapy ingredients to increase hair follicle size and therefore hair volume ,here we will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2
Study: NCT05631990
Drug: AD-209-1C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT05631990
Drug: AD-209 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT05631990
Drug: AD-209-1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT04903730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% sterile saline for injection delivered via the FOX MOBILE device.
Study: NCT05916339
Drug: Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Approvals — FDA: no, EMA: no, PMDA: no
Description: If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex
Study: NCT05222724
Drug: Tachifene
Normalized name: Pacifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
Study: NCT04708210
Drug: IBI319
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
Study: NCT05162768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
Study: NCT05306405
Drug: Vaginal Tablet
Normalized name: VAGINAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation
Study: NCT06461702
Drug: YOLT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IP is administered intravenously at the predetermined dose.
Study: NCT05976893
Drug: Statin
Normalized name: Statin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
Study: NCT05299866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
Study: NCT04985968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal administration
Study: NCT05333211
Drug: Ortho-R/PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
Study: NCT04733521
Drug: SC-43
Normalized name: acid violet 43
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-43 oral, every day of 21-day cycle
Study: NCT05663879
Drug: ID120040002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ID120040002
Study: NCT05663879
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06434025
Drug: Placebo of Iron Carboxymaltose
Normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution Sodium Chloride 0,9% 100 ml, IV, once.
Study: NCT05619887
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
Study: NCT06060704
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
Study: NCT05664516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal solution without oxytocin
Study: NCT05208281
Drug: GNR-055 1.0-2.0-3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
Study: NCT00451815
Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00451815
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04821063
Drug: ITF2357 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral